Markets | |
The world is becoming increasingly connected, and there’s no better proof of this than the hotel industry. Business travel and tourism fuel the global hotel industry, and there’s no sign of this growth slowing down. If you are interested in investing in the hotel industry, a review of ... Read the Full Story |
|
From Our Partners | | Tobacco, telecom, pipelines, and healthcare real estate trade at 10 to 15 times earnings while the index yields about 1 percent.
A free report highlights seven cash-generating stocks with a 5 percent forward yield floor and roughly 6.5 percent average cash yield, capped at two picks per sector.
Each pick includes coverage numbers and an honest bear case. Five of the seven have raised payouts for 17 to 56 straight years. | | Get the seven high-yield dividend stocks free now |
|
Markets | |
If someone were to say that we live in a “post-unicorn era,” they probably wouldn't be too far off. Some have been projecting such an era as far back as 2016, and with the recent issues surrounding WeWork, it's easy to see that if the unicorn era weren't dead before, it probably is now... Read the Full Story |
|
Markets | | Shares of DocuSign (NASDAQ: DOCU) finished last week at all-time highs after smashing analyst estimates for their earnings and revenue in their Q3 report which was released after Thursday’s session. This comes after upward guidance from management at their last quarterly release in September a... Read the Full Story |
|
From Our Partners | | One fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution rate.
Instead of guessing which AI stock wins, this fund delivers income every single Thursday, up to $1,051 a month.
Chief Income Strategist Tim Plaehn breaks down what's inside the fund and how the weekly payouts work. | | Watch the free video to see how the weekly payouts work |
|
Markets | | Scalping is a style of intraday trading that concentrates on taking high probability set-ups to profit off short-term price moves. Traders tend to use larger sized shares for smaller price gains. This style of trading requires high-probability strategies and disciplined execution. Over 70-percent of... Read the Full Story |
|
Markets | | Kroger’s (KR)management made two major missteps with the Restock Kroger plans. The first was their overaggressive plans to grow business in an attempt to compete with Walmart (WMT), Target (TGT), and Amazon (AMZN). The second was failing to realize the mistake soon enough. Now, with the compet... Read the Full Story |
|
From Our Partners | | More than 25 candidates were screened for share price between $1 and $5, market cap above $100 million, daily volume over 500,000 shares, and over $10 million in trailing revenue.
Only five stocks cleared every filter, spanning five different sectors. Two are profitable today, and one pays a substantial dividend.
The report also flags what could go wrong with each pick, including dilution and convertible debt. | | See the five stocks that survived this strict revenue screen |
|
Markets | | Salesforce.com (CRM) reported earnings this morning and shares are tumbling. The company reported a strong 33% topline growth for the 3rd quarter and provided robust guidance yet not quite good enough for investors. What we have is a classic case of unfulfilled expectations in an overexuberant marke... Read the Full Story |
|
Markets | |
Have you ever heard a trader talking about “reading the tape”? This is a term that advanced traders use to describe looking at Level II quotes. Level II quotes are great for traders because they allow us to get a little more information about the magnitude of the buying and selling of ... Read the Full Story |
|
Markets | | Shares of Veeva Systems (NYSE: VEEV) kept investors guessing after the company’s Q3 earnings last week. The stock whipped around a 12% range from Tuesday’s close on Wednesday following the release the previous evening. With markets shut on Thursday, they went into the Thanksgiving holida... Read the Full Story |
|
Healthcare | |
Pharmaceutical stocks are an important and interesting part of the healthcare market, and of the overall market as well. For investors who are interested in learning more about the pharmaceutical industry, a good place to start is with the following companies, which are some of the largest pharmac... Read the Full Story |
|
Markets | |
Money makes the world go around—at least in terms of driving a complex economy. Financial stocks are stocks issued by companies in the business of finance: banks, investment houses, credit unions, credit cards, and payment processing companies. These companies help individuals and organizati... Read the Full Story |
|
The Early Bird Stock Of The Day Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California. | | View Today's Stock Pick |
|
